The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

MINDHVHHQZYEEK-OYXVVHJOSA-N     9-[4-[(2S,3S,4R,5S)-3,4- dihydroxy-5-[[(2S...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Bactroban


Psychiatry related information on Bactroban

  • A new cream formulation of mupirocin developed to improve patient compliance was compared with systemic and topical antibiotics commonly used to treat primary and secondary skin infections [6].

High impact information on Bactroban


Chemical compound and disease context of Bactroban


Biological context of Bactroban

  • Gene knockout experiments demonstrated the importance of regions in mupirocin production, and complementation of the disrupted gene confirmed that the phenotypes were not due to polar effects [15].
  • Characterization of the mupirocin biosynthesis gene cluster from Pseudomonas fluorescens NCIMB 10586 [15].
  • By in-frame deletion analysis of selected tailoring open-reading frames we show that mupQ, mupS, mupT, and mupW are essential for mupirocin production, whereas mupO, mupU, mupV, and macpE are essential for production of PA-A but not PA-B [16].
  • An attempt to eradicate the resident's nasal carriage of MRSA in January 1986 failed; eradication of his carrier state was achieved only after treatment with mupirocin [17].
  • Mupirocin-resistant mutants of S. aureus 8325-4 were therefore generated to examine their ileS genotypes and the in vitro and in vivo fitness costs associated with them before and after compensatory evolution [18].

Anatomical context of Bactroban

  • These observations suggest that long-term use of low but bactericidal concentrations of mupirocin will not impair growth of fibroblasts in healing wounds [19].
  • Twenty noncarriers, 26 intermittent carriers, and 16 persistent carriers had nasal, throat, and perineum samples taken 1 day before and 5 weeks after mupirocin treatment (twice daily for 5 days) and assessed for growth of S. aureus [20].
  • We measured the delivery of mupirocin to the pharynx in three normal volunteers and two patients [21].
  • In P. aeruginosa, subinhibitory concentrations of mupirocin inhibited flagella formation, which was associated with reduced flagellin expression [22].
  • These results indicate that topical nasal treatment with mupirocin is effective to prevent carriage of bacteria into the trachea [23].

Associations of Bactroban with other chemical compounds

  • The emergence of mupirocin resistance in S. aureus highlights the need for a new topical antibiotic with the ability to inhibit high-level mupirocin-resistant strains and other emerging phenotypes, such as vancomycin-resistant and community-acquired methicillin-resistant isolates [24].
  • No MRSA isolate showed chlorhexidine resistance or high-level mupirocin resistance; however, we observed an association (P = 0.003) between low-level mupirocin resistance at study entry (prevalence, 23%) and subsequent treatment failure in both study arms [25].
  • Pseudomonic acid A (mupirocin) blocks protein synthesis in bacteria by inhibition of bacterial isoleucyl-tRNA synthetase [26].
  • Kinetic analysis of crude isoleucyl-tRNA synthetase from trained and untrained B. subtilis strains revealed differences in apparent Ki for mupirocin (resistant strain SB23T, Ki = 71.1 nM; sensitive strain SB23, Ki = 33.5 nM), while the Km for isoleucine remained unchanged (2.7 to 2.9 microM) [26].
  • When the individual circumstances of a medical facility justify eradication of MRSA colonization, a multidisciplinary approach that includes antibiotic therapy with oral minocycline and rifampin, along with topical mupirocin for those with nasal carriage, may be successful [27].

Gene context of Bactroban


Analytical, diagnostic and therapeutic context of Bactroban

  • Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients [5].
  • Median duration of catheter use was greater in the mupirocin than in the control group (37 versus 20 d, P < 0.01) [9].
  • Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage [32].
  • The effectiveness and safety of mupirocin calcium ointment applied to the anterior part of the nares for 5 days in the eradication of nasal carriage of Staphylococcus aureus was investigated in a placebo-controlled, double-blind study [33].
  • PCR amplification of genomic DNA from each mupirocin-resistant strain resulted in a 1.65-kb fragment, the predicted product from the intragenic mupA primers [34].


  1. Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. Silvian, L.F., Wang, J., Steitz, T.A. Science (1999) [Pubmed]
  2. Efficacy of mupirocin in cutaneous candidiasis. Rode, H., de Wet, P.M., Millar, A.J., Cywes, S. Lancet (1991) [Pubmed]
  3. Tandemly duplicated acyl carrier proteins, which increase polyketide antibiotic production, can apparently function either in parallel or in series. Rahman, A.S., Hothersall, J., Crosby, J., Simpson, T.J., Thomas, C.M. J. Biol. Chem. (2005) [Pubmed]
  4. Structural basis for the recognition of isoleucyl-adenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase. Nakama, T., Nureki, O., Yokoyama, S. J. Biol. Chem. (2001) [Pubmed]
  5. Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. Johnson, D.W., van Eps, C., Mudge, D.W., Wiggins, K.J., Armstrong, K., Hawley, C.M., Campbell, S.B., Isbel, N.M., Nimmo, G.R., Gibbs, H. J. Am. Soc. Nephrol. (2005) [Pubmed]
  6. Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Gisby, J., Bryant, J. Antimicrob. Agents Chemother. (2000) [Pubmed]
  7. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Reagan, D.R., Doebbeling, B.N., Pfaller, M.A., Sheetz, C.T., Houston, A.K., Hollis, R.J., Wenzel, R.P. Ann. Intern. Med. (1991) [Pubmed]
  8. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. Hoen, B., Paul-Dauphin, A., Hestin, D., Kessler, M. J. Am. Soc. Nephrol. (1998) [Pubmed]
  9. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. Sesso, R., Barbosa, D., Leme, I.L., Sader, H., Canziani, M.E., Manfredi, S., Draibe, S., Pignatari, A.C. J. Am. Soc. Nephrol. (1998) [Pubmed]
  10. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Kauffman, C.A., Terpenning, M.S., He, X., Zarins, L.T., Ramsey, M.A., Jorgensen, K.A., Sottile, W.S., Bradley, S.F. Am. J. Med. (1993) [Pubmed]
  11. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Goldfarb, J., Crenshaw, D., O'Horo, J., Lemon, E., Blumer, J.L. Antimicrob. Agents Chemother. (1988) [Pubmed]
  12. Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Schmitz, F.J., Fluit, A.C., Hafner, D., Beeck, A., Perdikouli, M., Boos, M., Scheuring, S., Verhoef, J., Köhrer, K., Von Eiff, C. Antimicrob. Agents Chemother. (2000) [Pubmed]
  13. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Jones, R.N., Fritsche, T.R., Sader, H.S., Ross, J.E. Antimicrob. Agents Chemother. (2006) [Pubmed]
  14. In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. Casewell, M.W., Hill, R.L. J. Antimicrob. Chemother. (1985) [Pubmed]
  15. Characterization of the mupirocin biosynthesis gene cluster from Pseudomonas fluorescens NCIMB 10586. El-Sayed, A.K., Hothersall, J., Cooper, S.M., Stephens, E., Simpson, T.J., Thomas, C.M. Chem. Biol. (2003) [Pubmed]
  16. Shift to Pseudomonic acid B production in P. fluorescens NCIMB10586 by mutation of mupirocin tailoring genes mupO, mupU, mupV, and macpE. Cooper, S.M., Laosripaiboon, W., Rahman, A.S., Hothersall, J., El-Sayed, A.K., Winfield, C., Crosby, J., Cox, R.J., Simpson, T.J., Thomas, C.M. Chem. Biol. (2005) [Pubmed]
  17. Mediastinitis following coronary artery bypass surgery: a 3-year review. Gaynes, R., Marosok, R., Mowry-Hanley, J., Laughlin, C., Foley, K., Friedman, C., Kirsh, M. J. Infect. Dis. (1991) [Pubmed]
  18. Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Hurdle, J.G., O'Neill, A.J., Ingham, E., Fishwick, C., Chopra, I. Antimicrob. Agents Chemother. (2004) [Pubmed]
  19. Effect of mupirocin on the growth and lifespan of human fibroblasts. Balin, A.K., Leong, I., Carter, D.M. J. Invest. Dermatol. (1987) [Pubmed]
  20. Effect of mupirocin treatment on nasal, pharyngeal, and perineal carriage of Staphylococcus aureus in healthy adults. Wertheim, H.F., Verveer, J., Boelens, H.A., van Belkum, A., Verbrugh, H.A., Vos, M.C. Antimicrob. Agents Chemother. (2005) [Pubmed]
  21. Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. Watanabe, H., Masaki, H., Asoh, N., Watanabe, K., Oishi, K., Kobayashi, S., Sato, A., Sugita, R., Nagatake, T. J. Clin. Microbiol. (2001) [Pubmed]
  22. Effects of mupirocin at subinhibitory concentrations on flagella formation in Pseudomonas aeruginosa and Proteus mirabilis. Horii, T., Morita, M., Muramatsu, H., Muranaka, Y., Kanno, T., Maekawa, M. J. Antimicrob. Chemother. (2003) [Pubmed]
  23. The preventive effects of mupirocin against nasotracheal intubation-related bacterial carriage. Takahashi, S., Minami, K., Ogawa, M., Miyamoto, H., Ikemura, K., Shigematsu, A., Taniguchi, H. Anesth. Analg. (2003) [Pubmed]
  24. Antibacterial activity of REP8839, a new antibiotic for topical use. Critchley, I.A., Young, C.L., Stone, K.C., Ochsner, U.A., Guiles, J., Tarasow, T., Janjic, N. Antimicrob. Agents Chemother. (2005) [Pubmed]
  25. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Harbarth, S., Dharan, S., Liassine, N., Herrault, P., Auckenthaler, R., Pittet, D. Antimicrob. Agents Chemother. (1999) [Pubmed]
  26. Mechanism of mupirocin transport into sensitive and resistant bacteria. Capobianco, J.O., Doran, C.C., Goldman, R.C. Antimicrob. Agents Chemother. (1989) [Pubmed]
  27. Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampin and topical mupirocin. Darouiche, R., Wright, C., Hamill, R., Koza, M., Lewis, D., Markowski, J. Antimicrob. Agents Chemother. (1991) [Pubmed]
  28. Interfering with different steps of protein synthesis explored by transcriptional profiling of Escherichia coli K-12. Sabina, J., Dover, N., Templeton, L.J., Smulski, D.R., Söll, D., LaRossa, R.A. J. Bacteriol. (2003) [Pubmed]
  29. Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Hodgson, J.E., Curnock, S.P., Dyke, K.G., Morris, R., Sylvester, D.R., Gross, M.S. Antimicrob. Agents Chemother. (1994) [Pubmed]
  30. Multiplex PCR for simultaneous detection of enterococcal genes vanA and vanB and staphylococcal genes mecA, ileS-2 and femB. Ramos-Trujillo, E., Pérez-Roth, E., Méndez-Alvarez, S., Claverie-Martín, F. Int. Microbiol. (2003) [Pubmed]
  31. Analysis and toxic overexpression in Escherichia coli of a staphylococcal gene encoding isoleucyl-tRNA synthetase. Chalker, A.F., Ward, J.M., Fosberry, A.P., Hodgson, J.E. Gene (1994) [Pubmed]
  32. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Doebbeling, B.N., Reagan, D.R., Pfaller, M.A., Houston, A.K., Hollis, R.J., Wenzel, R.P. Arch. Intern. Med. (1994) [Pubmed]
  33. Mupirocin treatment of nasal staphylococcal colonization. Scully, B.E., Briones, F., Gu, J.W., Neu, H.C. Arch. Intern. Med. (1992) [Pubmed]
  34. Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates. Ramsey, M.A., Bradley, S.F., Kauffman, C.A., Morton, T.M. Antimicrob. Agents Chemother. (1996) [Pubmed]
WikiGenes - Universities